Table 3.
Incidence of study outcomes during the follow-up period in the whole study population and in the two groups separately.
| Outcomes | All | HT | HT + COPD | P |
|---|---|---|---|---|
| MACE, n (%) | 205 (11.9) | 72 (5.9) | 133 (25.3) | 0.0001 |
| Incidence, n per 100 pts/yr | 2.47 | 1.22 | 5.55 | |
| Myocardial infarction | ||||
| Total, n (%) | 117 (6.8) | 48 (3.9) | 69 (13.1) | 0.0001 |
| Incidence, n per 100 pts/yr | 1.41 | 0.81 | 2.88 | |
| Non-fatal (%) | 111 (6.5) | 47 (3.9) | 64 (12.2) | 0.0001 |
| Incidence, n per 100 pts/yr | 1.34 | 0.79 | 2.67 | |
| Stroke | ||||
| Total, n (%) | 77 (4.4) | 19 (1.5) | 58 (11.0) | 0.0001 |
| Incidence, n per 100 pts/yr | 0.93 | 0.32 | 2.42 | |
| Non-fatal, n (%) | 63 (3.6) | 13 (1.0) | 50 (9.5) | 0.0001 |
| n per 100 pts/yr | 0.76 | 0.22 | 2.09 | |
MACE: major adverse cardiovascular events.